方法：回顾性分析2018-01/2020-08至我院接受玻璃体腔注射阿柏西普或雷珠单抗联合AGV植入术治疗的NVG闭角型青光眼期患者33例33眼的临床资料，其中阿柏西普组18眼，雷珠单抗组15眼。随访6mo，观察两组患者最佳矫正视力(BCVA)、眼压、新生血管消退及复发、玻璃体腔注射次数及术后并发症等情况，评估手术疗效。

结果：两组玻璃体腔首次注药术前与注药术后1wk眼压、BCVA均无差异(P>0.05)； AGV植入术后1wk，1、3、6mo眼压、BCVA与玻璃体腔首次注药术前均有差异(P<0.01)，但两组间各随访时间点眼压、BCVA均无差异(P>0.05)。随访期间，阿柏西普组平均注药次数(1.61±0.98次)与雷珠单抗组(1.80±0.86次)无差异(P>0.05)，且两组间新生血管复发率、术后早期及晚期并发症发生率及手术疗效均无差异(P>0.05)。

结论：玻璃体腔注射阿柏西普或雷珠单抗联合AGV植入术是治疗NVG的有效方法，二者临床疗效基本一致。

METHODS: A retrospective study. The clinical data of 33 cases(33 eyes)with NVG angle-closure glaucoma who were received intravitreal injection of aflibercept or ranibizumab with AGV implantation from January 2018 to August 2020 in our hospital were involved in this study. There were 18 eyes in the aflibercept group and 15 eyes in the ranibizumab group. All patients were followed-up for 6mo. The best-corrected visual acuity(BCVA), intraocular pressure, neovascularization, and postoperative complications were recorded and evaluated.

RESULTS: Before the first intravitreal injection and 1wk after intravitreal injection, the differences of intraocular pressure and BCVA in two groups were not statistically significant(P>0.05); The changes of intraocular pressure and BCVA before the first intravitreal injection and after AGV implant 1wk, 1, 3, 6mo were statistically significant in two groups(P<0.01), but there were no statistically significant differences intraocular pressure and BCVA between the two groups at each follow-up time point(P>0.05). There were no significant differences in average number of injections between aflibercept group(1.61±0.98)and ranibizumab group(1.80±0.86)(P>0.05). The differences of neovascular recurrence rate, incidence of early and late complications and surgical success rates were not statistically significant(P>0.05).

CONCLUSION: Intravitreal aflibercept or ranibizumab injection combined with AGV implantation is an effective treatment for NVG. The clinical efficacy of aflibercept and ranibizumab were similar.